{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,26]],"date-time":"2026-10-26T18:01:06Z","timestamp":1793037666204,"version":"4.5.0"},"reference-count":44,"publisher":"MDPI AG","issue":"3","license":[{"start":{"date-parts":[[2026,3,12]],"date-time":"2026-03-12T00:00:00Z","timestamp":1773273600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"name":"Medical University of Bialystok, Poland","award":["SUB\/1\/DN\/22\/001\/1149"],"award-info":[{"award-number":["SUB\/1\/DN\/22\/001\/1149"]}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Metabolites"],"abstract":"<jats:p>Introduction: Psoriasis is an autoimmune systemic disease of not entirely understood pathogenesis. It remains a significant therapeutic challenge and, due to its various comorbidities, has a remarkable detrimental effect on patients\u2019 wellbeing. Semaphorins (Sema) are a group of transmembrane, cell surface-attached and secretory proteins that might play an important role in psoriasis due to their presence on keratinocytes and the ability to stimulate the proinflammatory cytokine production. Aims: The study aimed to assess the concentration of Sema3A, Sema3E, Sema4A, Sema4D and Sema7A in serum samples of psoriatic patients and explore the correlation with disease activity and clinical and metabolic status. Materials and Methods: The study involved 60 patients with plaque psoriasis and 30 healthy volunteers matched for gender, age, and BMI. Results: The mean serum Sema3A, Sema3E and Sema4D levels were significantly higher in patients with psoriasis than controls (p &lt; 0.01, p &lt; 0.05 and p &lt; 0.05, respectively). Contrarily, Sema4A and Sema7A were significantly lower (p &lt; 0.001 and p &lt; 0.05 respectively). Significant positive correlation between Sema3A and UREA was noted. Sema3A levels were significantly higher in moderately ill and overweight patients (p &lt; 0.05, p &lt; 0.01, respectively) and in patients with longer-lasting psoriasis and male patients compared to controls (both p &lt; 0.05). Sema3E significantly negatively correlated with HDL and glucose levels. Sema4A was significantly lower in moderately and severe psoriatic patients (p &lt; 0.0001, p &lt; 0.01, respectively). Sema7A was significantly higher in moderately ill and overweight patients (p &lt; 0.05, p &lt; 0.01, respectively) and significantly lower in male patients and in those with longer lasting disease than in controls. None of the semaphorins correlated with psoriasis severity, total BMI, psoriasis duration and age. Conclusions: Psoriatic patients exhibited distinct alterations in circulating semaphorins, with significantly increased serum Sema3A, Sema3E and Sema4D, and reduced Sema4A and Sema7A compared with healthy subjects. Selected semaphorins demonstrated associations with metabolic parameters and patient characteristics, although none can serve as marker of disease severity. The findings indicate that semaphorins may reflect psoriasis-related systemic disturbances, but further studies are required to explore their potential with disease-associated metabolic or clinical profiles.<\/jats:p>","DOI":"10.3390\/metabo16030190","type":"journal-article","created":{"date-parts":[[2026,3,12]],"date-time":"2026-03-12T09:23:03Z","timestamp":1773307383000},"page":"190","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":1,"title":["Serum Semaphorin Alterations in Psoriasis: Links to Metabolic Status Rather than Disease Severity"],"prefix":"10.3390","volume":"16","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-8018-9960","authenticated-orcid":false,"given":"Anna","family":"Baran","sequence":"first","affiliation":[{"name":"Department of Dermatology and Venereology, Medical University of Bialystok, Zurawia 14 St., 15-540 Bialystok, Poland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1414-4569","authenticated-orcid":false,"given":"Anna","family":"Stepaniuk","sequence":"additional","affiliation":[{"name":"Department of Dermatology and Venereology, Medical University of Bialystok, Zurawia 14 St., 15-540 Bialystok, Poland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3985-4244","authenticated-orcid":false,"given":"Justyna Magdalena","family":"Hermanowicz","sequence":"additional","affiliation":[{"name":"Department of Pharmacodynamics, Medical University of Bialystok, Mickiewicza 2C St., 15-540 Bialystok, Poland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Beata","family":"Sieklucka","sequence":"additional","affiliation":[{"name":"Department of Monitored Pharmacotherapy, Medical University of Bialystok, Mickiewicza 2C St., 15-222 Bialystok, Poland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2254-7982","authenticated-orcid":false,"given":"Krystyna","family":"Pawlak","sequence":"additional","affiliation":[{"name":"Department of Monitored Pharmacotherapy, Medical University of Bialystok, Mickiewicza 2C St., 15-222 Bialystok, Poland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3751-0608","authenticated-orcid":false,"given":"Dariusz","family":"Pawlak","sequence":"additional","affiliation":[{"name":"Department of Pharmacodynamics, Medical University of Bialystok, Mickiewicza 2C St., 15-540 Bialystok, Poland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5923-910X","authenticated-orcid":false,"given":"Iwona","family":"Flisiak","sequence":"additional","affiliation":[{"name":"Department of Dermatology and Venereology, Medical University of Bialystok, Zurawia 14 St., 15-540 Bialystok, Poland"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1968","published-online":{"date-parts":[[2026,3,12]]},"reference":[{"key":"ref_1","doi-asserted-by":"crossref","first-page":"754","DOI":"10.1016\/S0140-6736(21)00184-7","article-title":"Therapeutics targeting the IL-23 and IL-17 pathway in psoriasis","volume":"397","author":"Ghoreschi","year":"2021","journal-title":"Lancet"},{"key":"ref_2","doi-asserted-by":"crossref","unstructured":"Patel, H.A., Revankar, R.R., Pedroza, S.T., Graham, S., and Feldman, S.R. (2023). The Genetic Susceptibility to Psoriasis and the Relationship of Linked Genes to Our Treatment Options. Int. J. Mol. Sci., 24.","DOI":"10.20944\/preprints202306.1290.v1"},{"key":"ref_3","doi-asserted-by":"crossref","first-page":"527","DOI":"10.1007\/s40257-024-00857-0","article-title":"Managing the Patient with Psoriasis and Metabolic Comorbidities","volume":"25","author":"Bellinato","year":"2024","journal-title":"Am. J. Clin. Dermatol."},{"key":"ref_4","doi-asserted-by":"crossref","first-page":"732","DOI":"10.1111\/1346-8138.15840","article-title":"Psoriasis: Comorbidities","volume":"48","author":"Yamazaki","year":"2021","journal-title":"J. Dermatol."},{"key":"ref_5","doi-asserted-by":"crossref","unstructured":"Sluczanowska-Glabowska, S., Jankowska, O., Staniszewska, M., and Pawlik, A. (2023). The Involvement of Semaphorins in the Pathogenesis of Skin Diseases. Int. J. Mol. Sci., 24.","DOI":"10.3390\/ijms242417235"},{"key":"ref_6","first-page":"1","article-title":"Semaphorins and their Signaling Mechanisms Methods","volume":"1493","author":"Alto","year":"2017","journal-title":"Mol. Biol."},{"key":"ref_7","doi-asserted-by":"crossref","first-page":"135","DOI":"10.1007\/s12026-022-09264-1","article-title":"Semaphorin-3A: A promising therapeutic tool in allergic rhinitis","volume":"70","author":"Lotfi","year":"2022","journal-title":"Immunol. Res."},{"key":"ref_8","doi-asserted-by":"crossref","first-page":"RP97654","DOI":"10.7554\/eLife.97654","article-title":"Downregulation of semaphorin 4A in keratinocytes reflects the features of non-lesional psoriasis","volume":"13","author":"Kume","year":"2024","journal-title":"Elife"},{"key":"ref_9","first-page":"204","article-title":"Semaphorin 5A promotes Th17 differentiation via PI3K-Akt-mTOR in systemic lupus erythematosus Arthritis","volume":"26","author":"Zhu","year":"2024","journal-title":"Res. Ther."},{"key":"ref_10","doi-asserted-by":"crossref","unstructured":"Alamri, A., Soussi Gounni, A., and Kung, S.K.P. (2017). View Point: Semaphorin-3E: An Emerging Modulator of Natural Killer Cell Functions?. Int. J. Mol. Sci., 18.","DOI":"10.3390\/ijms18112337"},{"key":"ref_11","doi-asserted-by":"crossref","first-page":"144637","DOI":"10.1016\/j.gene.2020.144637","article-title":"Semaphorin 4A, 4C, and 4D: Function comparison in the autoimmunity, allergy, and cancer","volume":"746","author":"Rajabinejad","year":"2020","journal-title":"Gene"},{"key":"ref_12","doi-asserted-by":"crossref","unstructured":"Lontos, K., Adamik, J., Tsagianni, A., Galson, D.L., Chirgwin, J.M., and Suvannasankha, A. (2018). The Role of Semaphorin 4D in Bone Remodeling and Cancer Metastasis. Front. Endocrinol., 9.","DOI":"10.3389\/fendo.2018.00322"},{"key":"ref_13","first-page":"892","article-title":"Semaphorin 7a participants in pterygium by regulating vascular endothelial growth factor","volume":"12","author":"Han","year":"2019","journal-title":"Int. J. Ophthalmol."},{"key":"ref_14","doi-asserted-by":"crossref","first-page":"104587","DOI":"10.1016\/j.mvr.2023.104587","article-title":"Semaphorin 7a regulates inflammatory mediators and permeability in retinal endothelial cells","volume":"150","author":"Liu","year":"2023","journal-title":"Microvasc. Res."},{"key":"ref_15","doi-asserted-by":"crossref","first-page":"199","DOI":"10.1016\/j.jdermsci.2007.02.002","article-title":"A hypothetical mechanism of intraepidermal neurite formation in NC\/Nga mice with atopic dermatitis","volume":"46","author":"Tominaga","year":"2007","journal-title":"J. Dermatol. Sci."},{"key":"ref_16","doi-asserted-by":"crossref","first-page":"176","DOI":"10.1016\/j.jdermsci.2011.02.004","article-title":"Semaphorin 7A on keratinocytes induces interleukin-8 production by monocytes","volume":"62","author":"Kamata","year":"2011","journal-title":"J. Dermatol. Sci."},{"key":"ref_17","doi-asserted-by":"crossref","first-page":"313","DOI":"10.1007\/s10456-023-09876-7","article-title":"Pathological angiogenesis: Mechanisms and therapeutic strategies","volume":"26","author":"Dudley","year":"2023","journal-title":"Angiogenesis"},{"key":"ref_18","doi-asserted-by":"crossref","first-page":"581","DOI":"10.1111\/j.1365-2133.2008.08889.x","article-title":"Altered expression of angiogenesis and lymphangiogenesis markers in the uninvolved skin of plaque-type psoriasis","volume":"160","author":"Henno","year":"2009","journal-title":"Br. J. Dermatol."},{"key":"ref_19","doi-asserted-by":"crossref","first-page":"2539","DOI":"10.21873\/anticanres.16421","article-title":"Sodium Valproate Enhances Semaphorin 3A-mediated Anti-angiogenesis and Tumor Growth Inhibition in Human Osteosarcoma Cells","volume":"43","author":"Sawai","year":"2023","journal-title":"Anticancer. Res."},{"key":"ref_20","doi-asserted-by":"crossref","first-page":"521","DOI":"10.2340\/00015555-1350","article-title":"Decreased expression of semaphorin-3A, a neurite-collapsing factor, is associated with itch in psoriatic skin","volume":"92","author":"Kou","year":"2012","journal-title":"Acta Derm. Venereol."},{"key":"ref_21","doi-asserted-by":"crossref","first-page":"1266","DOI":"10.1177\/0961203312456753","article-title":"Semaphorin 3A\u2014A marker for disease activity and a potential putative disease-modifying treatment in systemic lupus erythematosus","volume":"21","author":"Vadasz","year":"2012","journal-title":"Lupus"},{"key":"ref_22","doi-asserted-by":"crossref","unstructured":"Sang, Y., Tsuji, K., Nakanoh, H., Fukushima, K., Kitamura, S., and Wada, J. (2023). Role of Semaphorin 3A in Kidney Development and Diseases. Diagnostics, 13.","DOI":"10.20944\/preprints202308.2093.v1"},{"key":"ref_23","first-page":"640","article-title":"Semaphorin 3A in the Immune System: Twenty Years of Study","volume":"87","author":"Kiseleva","year":"2022","journal-title":"Biochemistry"},{"key":"ref_24","doi-asserted-by":"crossref","first-page":"1105","DOI":"10.1007\/s11010-024-05031-y","article-title":"CircZNF609 sponges miR-135b to up-regulate SEMA3A expression to alleviate ox-LDL-induced atherosclerosis","volume":"480","author":"Hou","year":"2025","journal-title":"Mol. Cell. Biochem."},{"key":"ref_25","doi-asserted-by":"crossref","first-page":"6695","DOI":"10.2147\/IJGM.S554075","article-title":"Plasma Semaphorin 3A as a Potential Biomarker for Cognitive Impairment in Cerebral Small Vessel Disease","volume":"18","author":"Ma","year":"2025","journal-title":"Int. J. Gen. Med."},{"key":"ref_26","doi-asserted-by":"crossref","first-page":"734","DOI":"10.1038\/s44161-024-00487-z","article-title":"Semaphorin-3A regulates liver sinusoidal endothelial cell porosity and promotes hepatic steatosis","volume":"3","author":"Eberhard","year":"2024","journal-title":"Nat. Cardiovasc. Res."},{"key":"ref_27","doi-asserted-by":"crossref","first-page":"e2415007","DOI":"10.1002\/advs.202415007","article-title":"Semaphorin 3E-Plexin D1 Axis Drives Lung Fibrosis through ErbB2-Mediated Fibroblast Activation","volume":"12","author":"Deng","year":"2025","journal-title":"Adv. Sci."},{"key":"ref_28","doi-asserted-by":"crossref","unstructured":"Paganoni, A.J.J., Amoruso, F., Pelayo, J.P., Calleja-P\u00e9rez, B., Vezzoli, V., Duminuco, P., Caramello, A., Oleari, R., Fern\u00e1ndez-Ja\u00e9n, A., and Cariboni, A. (2022). A Novel Loss-of-Function SEMA3E Mutation in a Patient with Severe Intellectual Disability and Cognitive Regression. Int. J. Mol. Sci., 23.","DOI":"10.3390\/ijms23105632"},{"key":"ref_29","doi-asserted-by":"crossref","first-page":"3858","DOI":"10.1038\/s41598-019-40325-y","article-title":"Peptide vaccine for semaphorin3E ameliorates systemic glucose intolerance in mice with dietary obesity","volume":"9","author":"Yoshida","year":"2019","journal-title":"Sci. Rep."},{"key":"ref_30","doi-asserted-by":"crossref","first-page":"4893","DOI":"10.5826\/dpc.1501a4893","article-title":"Real-life Experience of Bimekizumab in 27 Obese Patients with Plaque-type Psoriasis: A 24-week Multicenter Retrospective Study","volume":"15","author":"Fratton","year":"2025","journal-title":"Dermatol. Pract. Concept."},{"key":"ref_31","doi-asserted-by":"crossref","first-page":"2633","DOI":"10.7150\/jca.86739","article-title":"SEMA4A promotes prostate cancer invasion: Involvement of tumor microenvironment","volume":"14","author":"Liu","year":"2023","journal-title":"J. Cancer."},{"key":"ref_32","doi-asserted-by":"crossref","first-page":"200","DOI":"10.1007\/s10875-012-9798-5","article-title":"An inhibitory role for Sema4A in antigen-specific allergic asthma","volume":"33","author":"Morihana","year":"2013","journal-title":"J. Clin. Immunol."},{"key":"ref_33","doi-asserted-by":"crossref","first-page":"2396","DOI":"10.1016\/j.jid.2017.07.818","article-title":"Semaphorin4D Drives CD8+ T-Cell Lesional Trafficking in Oral Lichen Planus via CXCL9\/CXCL10 Upregulations in Oral Keratinocytes","volume":"137","author":"Ke","year":"2017","journal-title":"J. Investig. Dermatol."},{"key":"ref_34","doi-asserted-by":"crossref","first-page":"52","DOI":"10.1016\/j.clim.2015.12.012","article-title":"Soluble SEMA4D\/CD100: A novel immunoregulator in infectious and inflammatory diseases","volume":"163","author":"Maleki","year":"2016","journal-title":"Clin. Immunol."},{"key":"ref_35","doi-asserted-by":"crossref","first-page":"645","DOI":"10.1007\/s10067-023-06840-0","article-title":"Sema4D as a biomarker for Predicting rheumatoid arthritis disease activity","volume":"43","author":"Liu","year":"2024","journal-title":"Clin. Rheumatol."},{"key":"ref_36","doi-asserted-by":"crossref","first-page":"106886","DOI":"10.1016\/j.phrs.2023.106886","article-title":"Knockout of Sema4D alleviates liver fibrosis by suppressing AOX1 expression","volume":"195","author":"Wang","year":"2023","journal-title":"Pharmacol. Res."},{"key":"ref_37","doi-asserted-by":"crossref","first-page":"e10154","DOI":"10.15252\/emmm.201810154","article-title":"Inhibition of Sema4D\/PlexinB1 signaling alleviates vascular dysfunction in diabetic retinopathy","volume":"12","author":"Wu","year":"2020","journal-title":"EMBO Mol. Med."},{"key":"ref_38","first-page":"577","article-title":"Sema4D\/Plexin-B1 promotes the progression of osteosarcoma cells by activating Pyk2-PI3K-AKT pathway","volume":"21","author":"Li","year":"2021","journal-title":"J. Musculoskelet. Neuronal Interact."},{"key":"ref_39","doi-asserted-by":"crossref","first-page":"e43236","DOI":"10.1097\/MD.0000000000043236","article-title":"Sema4D combined with electrocardiographic parameters for predicting STEMI prognosis: Development and validation of a nomogram model","volume":"104","author":"Li","year":"2025","journal-title":"Medicine"},{"key":"ref_40","doi-asserted-by":"crossref","first-page":"110356","DOI":"10.1016\/j.abb.2025.110356","article-title":"Exploring the therapeutic potential of Diosgenin as a Semaphorin-4D antagonist against neurodegenerative disorders","volume":"768","author":"Gupta","year":"2025","journal-title":"Arch. Biochem. Biophys."},{"key":"ref_41","doi-asserted-by":"crossref","unstructured":"Zhang 1, Y., Jiang, X., Wu, D., Huang, H., Jia, G., and Zhao, G. (2024). Sema4D deficiency enhances glucose tolerance through GLUT2 retention in hepatocytes. J. Transl. Med., 22, 864.","DOI":"10.1186\/s12967-024-05694-7"},{"key":"ref_42","doi-asserted-by":"crossref","first-page":"26","DOI":"10.1038\/s41368-024-00289-w","article-title":"FUT8-mediated aberrant N-glycosylation of SEMA7A promotes head and neck squamous cell carcinoma progression","volume":"16","author":"Liu","year":"2024","journal-title":"Int. J. Oral. Sci."},{"key":"ref_43","doi-asserted-by":"crossref","first-page":"1027","DOI":"10.1080\/14737159.2023.2254693","article-title":"Serum Sema7A is increased in patients with acute aortic dissection","volume":"23","author":"Lyu","year":"2023","journal-title":"Expert. Rev. Mol. Diagn."},{"key":"ref_44","doi-asserted-by":"crossref","first-page":"01698","DOI":"10.1016\/j.molmet.2023.101698","article-title":"Sema7A protects against high-fat diet-induced obesity and hepatic steatosis by regulating adipo\/lipogenesis","volume":"70","author":"Lu","year":"2023","journal-title":"Mol. Metab."}],"container-title":["Metabolites"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/2218-1989\/16\/3\/190\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,3,12]],"date-time":"2026-03-12T10:18:22Z","timestamp":1773310702000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/2218-1989\/16\/3\/190"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,3,12]]},"references-count":44,"journal-issue":{"issue":"3","published-online":{"date-parts":[[2026,3]]}},"alternative-id":["metabo16030190"],"URL":"https:\/\/doi.org\/10.3390\/metabo16030190","relation":{},"ISSN":["2218-1989"],"issn-type":[{"value":"2218-1989","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,3,12]]}}}